Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: An updated analysis

Journal of the National Cancer Institute

Volumn 103, Issue 1, 2011, Pages 21-30

  Masi, Gianluca ^a   Vasile, Enrico ^a   Loupakis, Fotios ^a   Cupini, Samanta ^b   Fornaro, Lorenzo ^a   Baldi, Giacomo ^a   Salvatore, Lisa ^a   Cremolini, Chiara ^a   Stasi, Irene ^b   Brunetti, Isa ^a   Fabbri, Maria Agnese ^c   Puglisi, Martina ^c   Trenta, Patrizia ^c   Granetto, Cristina ^d   Chiara, Silvana ^e   Fioretto, Luisa ^b   Allegrini, Giacomo ^b   Crin, Lucio ^f   Andreuccetti, Michele ^a   Falcone, Alfredo ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d S CROCE E CARLE HOSPITAL   (Italy)

^e Istituto Nazionale Tumori   (Italy)

^f SANT'ANDREA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; RALTITREXED; TEGAFUR; URACIL;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; COMPARATIVE STUDY; CONTINUOUS INFUSION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 78651297593     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq456     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96.
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2000;18(3):581-592.
3. Loupakis F, Masi G, Vasile E, Falcone A. First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard frst? Curr Opin Oncol. 2008;20(4):459-465.
4. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27(22):3677-3683.
5. O'Neil BH, Goldberg RM. Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. Oncologist. 2008;13(10):1074-1083.
6. Seymour MT, Stenning SP, Cassidy J. Attitudes and practice in the management of metastatic colorectal cancer in Britain. Clin Oncol (R Coll Radiol). 1997;9(4):248-251.
7. Hochster HS. Stop and go: yes or no? J Clin Oncol. 2009;27(34): 5677-5679.
8. Hejna M, Kornek GV, Raderer M, et al. Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. Br J Cancer. 1998;78(6):760-764.
9. Maughan TS, James RD, Kerr DJ, et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet. 2003;361(9356):457-464.
10. Labianca R, Floriani I, Cortesi E, et al. Alternating versus continuous "FOLFIRI" in advanced colorectal cancer (ACC): a randomized "GISCAD" trial. J Clin Oncol. 2006;24(18s):147s. (suppl; abstr 3505).
11. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer- a GERCOR study. J Clin Oncol. 2006;24(3):394-400.
12. Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study. J Clin Oncol. 2009;27(34):5727-5733.
13. Falcone A, Masi G, Allegrini G, et al. Biweekly chemotherapy with oxali-platin, irinotecan, infusional fuorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol. 2002;20(19):4006-4014.
14. Masi G, Allegrini G, Cupini S, et al. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fuorouracil/leucovo-rin (FOLFOXIRI): results of phase II study with a simplifed biweekly schedule. Ann Oncol. 2004;15(12):1766-1772.
15. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumor response to frst-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Lancet. 2000;356(9227):373-378.
16. Johnson RK, Ringland C, Stokes JB, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol. 2006;7(9):741-746.
17. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16(8):1311-1319.
18. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fuoro-uracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22(7):1209-1214.
19. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fuoro-uracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fuorouracil, leucovorin, and irinotecan (FOLFIRI) as frst-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670-1676.
20. Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet. 2010;375(9719):1030-1047.
21. Kohne CH, Cunningham D, Di Costanzo F, et al. Clinical determinants of survival in patients with 5-fuorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002;13(2):308-317.
22. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-655.
23. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47(1):207-214.
24. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fuorouracil compared with fuorouracil alone as frst-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041-1047.
25. Cancer Therapy Evaluation Program NCI. Common Terminology Criteria for Adverse Events (CTCAE) v2.0 Online Instructions and Guidelines. https://webapps.ctep.nci.nih.gov/webobjs/ctc/webhelp/welcome- to-ctcae.htm. Accessed February 4, 2010.
26. Schoenfeld DA. Partial residuals for the proportional hazards regression model. Biometrika. 1982;39(2):499-503.
27. Sorbye H, Köhne CH, Sargent DJ, et al. Patient characteristics and strat-ifcation in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and strati-fcation. Ann Oncol. 2007;18(10):1666-1672.
28. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229-237.
29. Sanoff H, Sargent D, Campbell M, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008;26(35):5721-5727.
30. Pessino A, Sobrero A. Optimal treatment of metastatic colorectal cancer. Expert Rev Anticancer Ther. 2006;6(5):801-812.
31. Koopman M, Punt CJ. Chemotherapy, which drugs and when. Eur J Cancer. 2009;45(suppl 1):50-56.
32. Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unre-sectable metastatic colorectal cancer patients treated with 5-fuorouracil/ leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249(3):420-425.
33. Gallagher DJ, Kemeny N. Second-line management of metastatic colo-rectal cancer. Clin Colorectal Cancer. 2008;7(1):25-32.
34. Yeoh C, Chau I, Cunningham D, Norman AR, Hill M, Ross PJ. Impact of 5-fuorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. Clin Colorectal Cancer. 2003;3(2):102-107.
35. De Gramont A, Buyse M, Abrahantes JC, et al. Reintroduction of oxalipla-tin is associated with improved survival in advanced colorectal cancer. J Clin Oncol. 2007;25(22):3224-3229. (Pubitemid 47325605)
36. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irino-tecan, fuorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
37. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as frst-line therapy in metastatic colo-rectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013-2019.
38. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetux-imab in metastatic colorectal cancer. N Engl J Med. 2009;360(6):563-572.
39. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408-1417.
40. Masi G, Vasile E, Loupakis F, et al. Bevacizumab (BV) in combination with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) as frst-line treatment of metastatic colorectal cancer (mCRC): a phase II trial by the GONO group. Ann Oncol. 2009;20(suppl 7);viii12 (abstract#O-0017).